<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03662100</url>
  </required_header>
  <id_info>
    <org_study_id>16618</org_study_id>
    <secondary_id>I6T-MC-AMAR</secondary_id>
    <nct_id>NCT03662100</nct_id>
  </id_info>
  <brief_title>A Study of Two Formulations of LY3074828 in Healthy Participants</brief_title>
  <official_title>A Safety, Tolerability, and Pharmacokinetic Study of Injections of LY3074828 Solution Using Investigational 1-mL Pre-filled Syringes and Investigational 2-mL Autoinjector in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at the amount of the study drug, LY3074828, that gets
      into the blood stream and how long it takes the body to get rid of LY3074828 when given as
      different formulations. The tolerability of LY3074828 will also be evaluated and information
      about any side effects experienced will be collected.

      Screening is required within 28 days prior to the start of the study. For each participant,
      the study will last about 12 weeks, not including screening.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 6, 2018</start_date>
  <completion_date type="Actual">January 25, 2019</completion_date>
  <primary_completion_date type="Actual">January 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of LY3074828</measure>
    <time_frame>Baseline through Day 85</time_frame>
    <description>Pharmacokinetics: Cmax of LY3074828</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration versus Time Curve (AUC) of LY3074828</measure>
    <time_frame>Baseline through Day 85</time_frame>
    <description>Pharmacokinetics: AUC of LY3074828</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Scale (VAS) Pain Assessment</measure>
    <time_frame>Day 1, 0 hour</time_frame>
    <description>The VAS is a single-item participant-rated assessment of injection pain. Score is reported on a continuous scale of 0 to 100. Higher values indicate more pain.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3074828 Reference 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution formulation in pre-filled syringe (PFS) administered as subcutaneous (SC) injection in arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3074828 Reference 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution formulation in PFS administered as SC injection in thigh</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3074828 Reference 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution formulation in PFS administered as SC injection in abdomen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3074828 Test 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution formulation administered SC via an auto-injector (AI) in arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3074828 Test 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution formulation administered SC via an AI in thigh</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3074828 Test 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution formulation administered SC via an AI in abdomen</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LY3074828</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3074828 Reference 1</arm_group_label>
    <arm_group_label>LY3074828 Reference 2</arm_group_label>
    <arm_group_label>LY3074828 Reference 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3074828</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3074828 Test 1</arm_group_label>
    <arm_group_label>LY3074828 Test 2</arm_group_label>
    <arm_group_label>LY3074828 Test 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Auto-injector (AI)</intervention_name>
    <description>AI to administer LY3074828</description>
    <arm_group_label>LY3074828 Test 1</arm_group_label>
    <arm_group_label>LY3074828 Test 2</arm_group_label>
    <arm_group_label>LY3074828 Test 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prefilled syringe (PFS)</intervention_name>
    <description>PFS to administer LY3074828</description>
    <arm_group_label>LY3074828 Reference 1</arm_group_label>
    <arm_group_label>LY3074828 Reference 2</arm_group_label>
    <arm_group_label>LY3074828 Reference 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Exclusion Criteria:

          -  Must not have an average weekly alcohol intake that exceeds 21 units/week (males) and
             14 units/week (females)

          -  Must not show evidence of active or latent tuberculosis (TB)

          -  Must not have received live vaccine(s) (including attenuated live vaccines and those
             administered intranasally) within 8 weeks of screening, or intend to during the study

          -  Must not have been treated with steroids within 1 month of screening, or intend to
             during the study

          -  Must not be immunocompromised

          -  Must not have received treatment with biologic agents (e.g. monoclonal antibodies,
             including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior
             to Day 1

          -  Must not have significant allergies to humanised monoclonal antibodies

          -  Must not have clinically significant multiple or severe drug allergies, or intolerance
             to topical corticosteroids, or severe post treatment hypersensitivity reactions

          -  Must not have had lymphoma, leukemia, or any malignancy within the past 5 years except
             for basal cell or squamous epithelial carcinomas of the skin that have been resected
             with no evidence of metastatic disease for 3 years

          -  Must not have had breast cancer within the past 10 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 1, 2019</verification_date>
  <study_first_submitted>September 5, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <last_update_submitted>February 18, 2019</last_update_submitted>
  <last_update_submitted_qc>February 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

